Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Published 2024-04-09, 04:50 p/m
OCX
-

IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation¯(Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial results and highlights.

Interested parties may access the live call via telephone by dialing toll free (888) 550-5422 for both domestic and international callers. Once dialed in, ask to be joined to the Oncocyte Corporation call.

The live webcast of the call may be accessed by visiting the Events & Presentations section of the Company's website at  https://investors.oncocyte.com. A replay of the webcast will be available on the Company's website shortly after the conclusion of the call.¯

CONFERENCE CALL DETAILSParticipant Toll-Free Dial-In Number: (800) 715-9871Participant Toll Dial-In Number: +1 (646) 307-1963Conference ID: 2701195

Webcasthttps://events.q4inc.com/attendee/233145459

About Oncocyte

Oncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test, GraftAssure™ is a research use only blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

Contact:Jeff RamsonPCG Advisory(646) 863-6893jramson@pcgadvisory.com

Source: OncoCyte (NASDAQ:OCX) Corporation

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.